Abcam, ab269660, Human TLE1 knockout MCF7 cell lysate

Size: 1Kit
TLE1 KO cell lysate available now. KO validated by Next Generation Sequencing. Free of charge wild type control included. Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift = 100%.
Key facts
Cell type:MCF7,
Species or organism:Human,
Tissue:Breast,
Knockout validation:Next Generation Sequencing,
Mutation description:Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift = 100%,
Disease:Adenocarcinoma

Product details:
Western blot data indicates that the CRISPR gene edit may have resulted in a truncation of the protein of interest. Please see data images.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TLE1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Next Generation Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Transducin-Like Enhancer of Split 1 also known as TLE1 is a transcriptional corepressor well-known for its involvement in Notch and Wnt signaling pathways. TLE1 has a molecular mass of approximately 77 kDa. This protein is expressed in various tissues including the brain heart and lung highlighting its involvement in multiple biological systems. Researchers recognize its importance in modulating gene expression through interactions with different transcription factors.
Biological function summary
The TLE1 protein plays a role in embryonic development by regulating the transcription of genes critical for cell differentiation. TLE1 forms part of a complex with other proteins to exert its corepressive function effectively. Through these interactions TLE1 is involved in differentiation processes in cells such as MCF-7 a breast cancer cell line influencing cellular behavior and function.
Pathways
TLE1 influences the Notch and Wnt signaling pathways essential for cell fate determination and proliferation. Its interaction with key proteins like β-catenin and Notch receptor proteins connects it to these pathways modulating the transcription of target genes. TLE1's role in these pathways is important for maintaining balanced cellular processes and preventing abnormal cell growth.
TLE1 is linked to various forms of cancer including synovial sarcoma and breast cancer. Its overexpression has been observed in these cancers often in conjunction with other proteins like BCL2 supporting cell survival and resisting apoptosis. TLE1's involvement in these diseases makes it a target for therapeutic strategies aimed at modulating its activity to inhibit tumor progression.